There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ultragenyx Pharmaceutical, Inc. (RARE), Matinas BioPharma (MTNB) and ESSA Pharma Inc (EPIX) with bullish sentiments.
Ultragenyx Pharmaceutical, Inc. (RARE)
Cowen & Co. analyst Yaron Werber maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. yesterday and set a price target of $79. The company’s shares closed last Monday at $59.69.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 10.3% and a 61.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Prevail Therapeutics Inc, and Stoke Therapeutics Inc.
Currently, the analyst consensus on Ultragenyx Pharmaceutical, Inc. is a Strong Buy with an average price target of $79.80, implying a 34.0% upside from current levels. In a report issued on August 2, Wedbush also initiated coverage with a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
Matinas BioPharma (MTNB)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Matinas BioPharma on August 13 and set a price target of $3. The company’s shares closed last Monday at $0.70.
McCarthy observed:
“Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin).”
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -24.1% and a 21.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Hancock Jaffe Laboratories Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Matinas BioPharma is a Strong Buy with an average price target of $4, implying a 479.7% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4 price target.
ESSA Pharma Inc (EPIX)
In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on ESSA Pharma Inc, with a price target of $14. The company’s shares closed last Monday at $1.68, close to its 52-week low of $1.41.
Pantginis commented:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $14 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our current target is based 100% on the projected lead Aniten asset for prostate cancer. Factors that could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.0% and a 28.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ESSA Pharma Inc with a $14 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
